Loading...

Diana Lewez Hanna, MD

TitleAssistant Professor of Clinical Medicine
InstitutionUniversity of Southern California
DepartmentMedicine
AddressIRD 2020 Zonal Ave
Off Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    2005Phi Sigma Honor Society
    2005Phi Kappa Phi Honor Society
    University of California, Davis2012Professionalism of the Year in Internal Medicine Award
    Division of Oncology, USC2014  - 2015Chief Fellow

    Collapse Overview 
    Collapse Overview
    Dr. Hanna's research interests include investigation of predictive and prognostic biomarkers in gastrointestinal malignancies and clinical trial protocol development with Dr. Heinz-Josef Lenz.

    Dr. Hanna earned her medical degree from University of California, Davis. She then went on to complete her Hematology/Oncology Fellowship at USC, where she served as Chief Fellow.


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hanna D, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer. 2018 Mar 14. PMID: 29636300.
      View in: PubMed
    2. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna D, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer Res. 2018 Feb 15; 24(4):784-793. PMID: 29208668.
      View in: PubMed
    3. Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna D, McSkane M, Soni S, Zhang W, Lenz HJ. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta. 2017 12; 1868(2):439-448. PMID: 28939182.
      View in: PubMed
    4. Ricker CN, Hanna D, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer. 2017 Oct 01; 123(19):3732-3743. PMID: 28640387.
      View in: PubMed
    5. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 07 15; 141(2):383-392. PMID: 28369940.
      View in: PubMed
    6. Berger MD, Yamauchi S, Cao S, Hanna D, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017 05; 77:13-20. PMID: 28347919.
      View in: PubMed
    7. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1(5):e000097. PMID: 27843641.
      View in: PubMed
    8. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Mol Cancer Ther. 2016 11; 15(11):2814-2821. PMID: 27535973.
      View in: PubMed
    9. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna D, Lenz HJ. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Aug 16; 7(33):53668-53678. PMID: 27449091.
      View in: PubMed
    10. Miyamoto Y, Hanna D, Zhang W, Baba H, Lenz HJ. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. Clin Cancer Res. 2016 Aug 15; 22(16):3999-4004. PMID: 27340276; PMCID: PMC4987228 [Available on 02/15/17].
    11. Hanna D, Lenz HJ. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1091-108. PMID: 27031164.
      View in: PubMed
    12. Matsusaka S, Zhang W, Cao S, Hanna D, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther. 2016 06; 15(6):1405-11. PMID: 26983880; PMCID: PMC4893985 [Available on 06/01/17].
    13. Matsusaka S, Hanna D, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res. 2016 Jul 01; 22(13):3218-26. PMID: 26839145; PMCID: PMC4930688 [Available on 07/01/17].
    14. Ning Y, Hanna D, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. PMID: 26227487; PMCID: PMC4596790 [Available on 10/01/16].
    15. Yang D, Hanna D, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2014 Dec 01; 120(23):3707-16. PMID: 25081299.
      View in: PubMed
    16. Ning Y, Gerger A, Zhang W, Hanna D, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2014 Feb; 13(2):528-39. PMID: 24170770; PMCID: PMC3945969.
    17. Hanna D, White RH, Wun T. Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol. 2013 Oct; 88(1):19-29. PMID: 23522921; PMCID: PMC3742654.